The Senate Finance Committee held a hearing on Wednesday to examine the pricing of Novo Nordisk’s diabetes drugs, Ozempic and Wegovy. Witnesses testified about the high costs of the medications and the impact on patients and healthcare systems. Novo Nordisk’s CEO, Lars Fruergaard Jorgensen, defended the prices, stating that the company invests heavily in research and development.